[Federal Register Volume 63, Number 90 (Monday, May 11, 1998)]
[Notices]
[Pages 26018-26019]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-12327]
[[Page 26017]]
_______________________________________________________________________
Part IV
Department of Health and Human Services
_______________________________________________________________________
National Institutes of Health
_______________________________________________________________________
Recombinant DNA Research: Actions Under the Guidelines; Notice
Federal Register / Vol. 63, No. 90 / Monday, May 11, 1998 / Notices
[[Page 26018]]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Recombinant DNA Research: Actions Under the Guidelines
AGENCY: National Institutes of Health (NIH), PHS, DHHS.
ACTION: Notice of Actions Under the NIH Guidelines for Research
Involving Recombinant DNA Molecules (NIH Guidelines).
-----------------------------------------------------------------------
SUMMARY: This notice sets forth actions to be taken by the Director,
National Institutes of Health, under the NIH Guidelines for Research
Involving Recombinant DNA Molecules (59 FR 34496, amended 59 FR 40170,
60 FR 20726, 61 FR 1482, 61 FR 10004, 62 FR 4782, 62 FR 53335, 62 FR
56196, 62 FR 59032, and 63 FR 8052).
FOR FURTHER INFORMATION CONTACT:
Background documentation and additional information can be obtained
from the Office of Recombinant DNA Activities (ORDA), National
Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302,
Bethesda, Maryland 20892-7010, Phone 301-496-9838, FAX 301-496-9839.
The ORDA web site is located at http://www.nih.gov/od/orda/ for further
information about the office.
SUPPLEMENTARY INFORMATION: Today's actions are being promulgated under
the NIH Guidelines for Research Involving Recombinant DNA Molecules
(NIH Guidelines). The proposed actions were published for comment in
the Federal Register on February 11, 1998 (63 FR 7054), and reviewed by
the NIH Recombinant DNA Advisory Committee (RAC) at its meeting on
March 10, 1998.
I. Amendment to Appendix M-I, Submission Requirements--Human Gene
Transfer Experiments, Under the NIH Guidelines Regarding Electronic
Submission of Protocols
I-A. Background Information and Decisions on Actions Under the NIH
Guidelines
Appendix M-I, Submission Requirements--Human Gene Transfer
Experiments, of the NIH Guidelines, stipulates requirements for
submission of documents to ORDA. In January 1998, Dr. C. Estuardo
Aguilar-Cordova, a member of the RAC, participated in a pilot test with
ORDA staff regarding electronic submission of documents to ORDA. In
this test, the documents submitted electronically included a human gene
transfer protocol; responses to Appendices M-II through M-V, Points to
Consider in the Design and Submission of Protocols for the Transfer of
Recombinant DNA Molecules into One or More Human Subjects (Points to
Consider); and the ORDA registration document. The 82-page electronic
submission, including tables, satisfactorily proved the efficiency and
effectiveness of using this method for submission of protocols.
ORDA recognizes that electronic submission of documents is an
accepted standard of practice within the scientific community;
therefore, this practice is not novel. The practice of using this
medium to submit formal protocols to ORDA, however, is novel and
requires amendments to the NIH Guidelines. As a result, ORDA proposed
to amend Appendix M-I of the NIH Guidelines to provide guidance to
investigators regarding optional electronic submission procedures.
Electronic submission of human gene transfer protocols to ORDA
offers several distinct advantages over the current practice of
submitting protocols by printed matter, including: (1) ORDA can review
protocols more expeditiously because they are received immediately; (2)
electronic submission allows ORDA to search protocols electronically
for keywords or phrases; (3) registration tasks performed at ORDA will
be reduced substantially because the investigator has already completed
most of the registration document as part of the electronic submission;
and (4) ORDA can facilitate RAC review of the protocol by forwarding
the complete protocol to RAC members electronically.
Appendix M-I is proposed to read:
``Appendix M-I. Submission Requirements--Human Gene Transfer
Experiments
``Investigators must submit the following material (see
exemption in Appendix M-VIII-A, Footnotes of Appendix M) to the
Office of Recombinant DNA Activities, National Institutes of Health/
MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, Maryland
20892-7010, Phone 301-496-9838, FAX 301-496-9839. Investigators may
submit this material electronically and can obtain specific
instructions from the ORDA home page (http://www.nih.gov/od/orda)
regarding electronic submission requirements. For all submissions,
whether printed or electronic, ORDA will confirm receipt within
three working days after receiving the submission. Investigators
should contact ORDA if they do not receive this confirmation.
``Proposals in printed form and/or in an electronic version
shall be submitted to NIH/ORDA in the following order: (1)
Scientific abstract; (2) non-technical abstract; (3) Responses to
Appendix M-II through M-V, Description of the Proposed, Informed
Consent, Privacy and Confidentiality, and Special Issues (the
pertinent responses can be provided in the protocol or as an
appendix to the protocol); (4) clinical protocol as approved by the
local Institutional Biosafety Committee and Institutional Review
Board; (5) Informed Consent document as approved by the
Institutional Review Board (see Appendix M-III, Informed Consent);
(6) appendices (including tables, figures, and manuscripts); and (7)
curricula vitae--no more than two pages for each key professional
person in biographical sketch format.
``All submissions must include Institutional Biosafety Committee
(IBC) and Institutional Review Board (IRB) approvals and their
deliberations pertaining to your protocol. IBC approval must be
obtained from each institution at which recombinant DNA material
will be administered to human subjects (as opposed to each
institution involved in the production of vectors for human
application and each institution at which there is ex vivo
transduction of recombinant DNA material into target cells for human
application). Because these written IBC and IRB approvals require
appropriate signatures, investigators cannot submit them
electronically. Investigators should submit these signed approvals
either by mail or by facsimile trnasmission.
``Investigational New Drug (IND) applications shall be submitted
to the FDA in the format described in 21 CFR, Chapter I, Subchapter
D, Part 312, Subpart B, Section 23, IND Content and Format.
Submissions to the FDA should be sent to the Division of
Congressional and Public Affairs, Document Control Center, HFM-99,
Center for Biologics Evaluation and Research, 1401 Rockville Pike,
Rockville, Maryland 20852-1448.
``Note: NIH/ORDA will accept submission material at any time.
However, if a protocol is submitted less than eight weeks before a
scheduled RAC meeting and subsequently is recommended for public
discussion by the full RAC, the public discussion of that protocol
will be deferred until the next scheduled RAC meeting. This eight-
week period is needed to ensure adequate time for review by the
committee members.''
During the March 10, 1998, RAC meeting, a motion was made that the
RAC accept the proposed action published in the Federal Register of
February 11, 1998 (63 FR 7054) to permit submission of human gene
transfer protocols to ORDA for registration in an optional electronic
format, as opposed to the printed materials. The motion passed by a
vote of 9 in favor, 0 opposed, and 1 abstention.
The actions are detailed in Section I-B--Summary of Actions. I
accept the RAC recommendations, and the NIH Guidelines will be amended
accordingly.
[[Page 26019]]
I-B. Summary of Actions
I-B-1. Amendments to Appendix M-I. Submission Requirements--Human Gene
Transfer Experiments
Appendix M-I is to be amended to read:
``Section M-I. Submission Requirements--Human Gene Transfer
Experiments
``Investigators must submit the following material (see
exemption in Appendix M-VIII-A, Footnotes of Appendix M) to the
Office of Recombinant DNA Activities, National Institutes of Health/
MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, Maryland
20892-7010, Phone 301-496-9838, FAX 301-496-9839. Investigators may
submit this material electronically and can obtain specific
instructions from the ORDA home page (http://www.nih.gov/od/or/orda)
regarding electronic submission requirements. For all submissions,
whether printed or electronic, ORDA will confirm receipt within
three working days after receiving the submission. Investigators
should contact ORDA if they do not receive this confirmation.
``Proposals in printed form and/or in an electronic version
shall be submitted to NIH/ORDA in the following order: (1)
Scientific abstract; (2) non-technical abstract; (3) Responses to
Appendix M-II through M-V, Description of the Proposal, Informed
Consent, Privacy and Confidentiality, and Special Issues (the
pertinent responses can be provided in the protocol or as an
appendix to the protocol); (4) clinical protocol as approved by the
local Institutional Biosafety Committee and Institutional Review
Board; (5) Informed Consent document as approved by the
Institutional Review Board (see Appendix M-III, Informed Consent);
(6) appendices (including tables, figures, and manuscripts); and (7)
curricula vitae--no more than two pages for each key professional
person in biographical sketch format.
``All submissions must include Institutional Biosafety Committee
(IBC) and Institutional Review Board (IRB) approvals and their
deliberations pertaining to your protocol. IBC approval must be
obtained from each institution at which recombinant DNA material
will be administered to human subjects (as opposed to each
institution involved in the production of vectors for human
application and each institution at which there is ex vivo
transduction of recombinant DNA material into target cells for human
application). Because these written IBC and IRB approvals require
appropriate signatures, investigators cannot submit them
electronically. Investigators should submit these signed approvals
either by mail or by facsimile transmission.
``Investigational New Drug (IND) applications shall be submitted
to the FDA in the format described in 21 CFR, Chapter I, Subchapter
D, Part 312, Subpart B, Section 23, IND Content and Format.
Submissions to the FDA should be sent to the Division of
Congressional and Public Affairs, Document Control Center, HFM-99,
Center for Biologics Evaluation and Research, 1401 Rockville Pike,
Rockville, Maryland 20852-1448.
``Note: NIH/ORDA will accept submission material at any time.
However, if a protocoal is submitted less than eight weeks before a
scheduled RAC meeting and subsequently is recommended for public
discussion by the full RAC, the public discussion of that protocol
will be deferred until the next scheduled RAC meeting. This eight-
week period is needed to ensure adequate time for review by the
committee members.''
OMB's ``Mandatory Information Requirements for Federal
Assistance Program Announcements'' (45 FR 39592) requires a
statement concerning the official government programs contained in
the Catalog of Federal Domestic Assistance. Normally NIH lists in
its announcements the number and title of affected individual
programs for the guidance of the public. Because the guidance in
this notice covers virtually every NIH and Federal research program
in which DNA recombinant molecule techniques could be used, it has
been determined not to be cost effective or in the public interest
to attempt to list these programs. Such a list would likely require
several additional pages. In addition, NIH could not be certain that
every Federal program would be included as many Federal agencies, as
well as private organizations, both national and international, have
elected to follow the NIH Guideline. In lieu of the individual
program listing, NIH invites readers to direct questions to the
information address above about whether individual programs listed
in the Catalog of Federal Domestic Assistance are affected.
Dated: April 30, 1998.
Harold Varmus,
Director, National Institutes of Health.
[FR Doc. 98-12327 Filed 5-8-98; 8:45 am]
BILLING CODE 4140-01-M